Literature DB >> 20562161

Modeling lesion counts in multiple sclerosis when patients have been selected for baseline activity.

C J Morgan1, I B Aban, C R Katholi, G R Cutter.   

Abstract

The number of new gadolinium-enhancing lesions discovered via magnetic resonance imaging is a well-established outcome for multiple sclerosis studies, especially Phase II Studies. Due to the high cost of magnetic resonance imaging scans, many investigators select participants for the presence of lesions. While this selection procedure is thought to improve the power of inferences, the effect of screening for baseline activity on parameter estimation and interval coverage has not yet been examined. The objective of this study was to investigate the performance of the negative binomial distribution for modeling lesion count data in multiple sclerosis when patients have been selected for activity on a baseline scan. We performed computer simulations to investigate the influence of the screening process on inferences made using a negative binomial model about treatment effects in two independent samples. We also demonstrate how the statistical properties of screening can be incorporated into trial design. We demonstrate that when the negative binomial distribution is used to model lesion counts, while screening for baseline activity improves point estimation, this practice also has the potential to decrease interval coverage and inflate the Type I error rate. For data that is to be modeled using a negative binomial distribution, screening for baseline activity can create a trade-off between cost effectiveness and a higher than desired false positive rate that must be carefully considered in planning Phase II trials.

Entities:  

Mesh:

Year:  2010        PMID: 20562161      PMCID: PMC3352326          DOI: 10.1177/1352458510373110

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  12 in total

Review 1.  Statistical issues related to the use of MRI data in multiple sclerosis.

Authors:  Maria Pia Sormani; Massimo Filippi
Journal:  J Neuroimaging       Date:  2007-04       Impact factor: 2.486

2.  Inferences and Power Analysis Concerning Two Negative Binomial Distributions with An Application to MRI Lesion Counts Data.

Authors:  Inmaculada B Aban; Gary R Cutter; Nsoki Mavinga
Journal:  Comput Stat Data Anal       Date:  2008-01-15       Impact factor: 1.681

3.  The distribution of the magnetic resonance imaging response to glatiramer acetate in multiple sclerosis.

Authors:  M P Sormani; P Bruzzi; G Comi; M Filippi
Journal:  Mult Scler       Date:  2005-08       Impact factor: 6.312

4.  European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.

Authors:  G Comi; M Filippi; J S Wolinsky
Journal:  Ann Neurol       Date:  2001-03       Impact factor: 10.422

5.  The distribution of new enhancing lesion counts in multiple sclerosis: further explorations.

Authors:  Ij van den Elskamp; Dl Knol; Bmj Uitdehaag; F Barkhof
Journal:  Mult Scler       Date:  2008-10-09       Impact factor: 6.312

6.  Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

Authors:  L D Jacobs; D L Cookfair; R A Rudick; R M Herndon; J R Richert; A M Salazar; J S Fischer; D E Goodkin; C V Granger; J H Simon; J J Alam; D M Bartoszak; D N Bourdette; J Braiman; C M Brownscheidle; M E Coats; S L Cohan; D S Dougherty; R P Kinkel; M K Mass; F E Munschauer; R L Priore; P M Pullicino; B J Scherokman; R H Whitham
Journal:  Ann Neurol       Date:  1996-03       Impact factor: 10.422

7.  Modelling MRI enhancing lesion counts in multiple sclerosis using a negative binomial model: implications for clinical trials.

Authors:  M P Sormani; P Bruzzi; D H Miller; C Gasperini; F Barkhof; M Filippi
Journal:  J Neurol Sci       Date:  1999-02-01       Impact factor: 3.181

8.  Clinical trials of multiple sclerosis monitored with enhanced MRI: new sample size calculations based on large data sets.

Authors:  M P Sormani; D H Miller; G Comi; F Barkhof; M Rovaris; P Bruzzi; M Filippi
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-04       Impact factor: 10.154

9.  The distribution of magnetic resonance imaging response to interferonbeta-1b in multiple sclerosis.

Authors:  Maria Pia Sormani; Paolo Bruzzi; Karola Beckmann; Ludwig Kappos; David H Miller; Chris Polman; Carlo Pozzilli; Alan J Thompson; Klaus Wagner; Massimo Filippi
Journal:  J Neurol       Date:  2005-07-18       Impact factor: 4.849

10.  Modelling new enhancing MRI lesion counts in multiple sclerosis.

Authors:  M P Sorman; P Bruzzi; M Rovaris; F Barkhof; G Comi; D H Miller; G R Cutter; M Filipp
Journal:  Mult Scler       Date:  2001-10       Impact factor: 6.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.